Home › Companies › OLEMA PHARMACEUTICALS INC. › 2023-2024

OLEMA PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and OLEMA PHARMACEUTICALS INC.’s Form 8-K, filed 2024-06-14 (Item 5.07 on EDGAR). Page generated 04 October 2026.

6Reported items
147Asset managers
923Fund votes
2024-06-13Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore OLEMA PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by OLEMA PHARMACEUTICALS INC.

These tallies are OLEMA PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-14 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

OLEMA PHARMACEUTICALS INC. — official shareholder meeting results, meeting held 2024-06-13
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Ian Clark	33,874,399	--	--	12,094,961	2,425,736	Majority: yes
Elect Director: Sandra Horning, M.D.	40,102,098	--	--	5,867,262	2,425,736	Majority: yes
Elect Director: Gorjan Hrustanovic, Ph.D.	44,334,757	--	--	1,634,603	2,425,736	Majority: yes
Proposal 2: Advisory Vote on Executive Compensation Final Voting Results	45,174,223	787,068	8,069	--	2,425,736	Passed
Proposal 3: Ratification of Selection of Independent Registered Public Accounting Firm Final Voting Results	48,366,695	19,160	9,241	--	--	Passed

Source: OLEMA PHARMACEUTICALS INC., Form 8-K, filed with the SEC on 2024-06-14 — read the filing on EDGAR.

How asset managers voted at the OLEMA PHARMACEUTICALS INC. 2023-2024 meeting

Each item below shows how the 147 asset managers that disclosed a OLEMA PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of OLEMA PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Approval, on an advisory basis, of the compensation of the Company's named executive officers.

SECTION 14A SAY-ON-PAY VOTESCompany result: Passed

Combines 4 wordings of this item as funds reported it.

98% Passed · of votes cast

FOR 98%

FOR: 45,174,223AGAINST: 787,068

OLEMA PHARMACEUTICALS INC.’s own tally for this item (“Proposal 2: Advisory Vote on Executive Compensation Final Voting Results”): 45,174,223 for, 787,068 against — passed, per its Form 8-K filed 2024-06-14 (Item 5.07). Of all 55,867,863 outstanding shares: 81% for, 1% against (82% of the company cast a for/against vote).

The 143 asset managers below cast 99% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.

FOR 99%

FOR: 98.8%AGAINST: 1.2%

Largest asset managers voting on “Approval, on an advisory basis, of the compensation of the Company's named executive officers.” at OLEMA PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
New York Life	18,013,321	0	For
BVF INC/IL	9,135,893	0	For
Paradigm Biocapital Advisors LP	4,328,462	0	For
State Street	4,292,874	851	For
Deep Track Capital, LP	2,748,295	0	For
Vanguard	2,455,623	0	For
MPM BioImpact LLC	1,959,800	0	For
BlackRock	1,885,220	4,228	For
Vivo Capital, LLC	1,873,704	0	For
Logos Global Management LP	1,800,000	0	For
Victory Capital	1,695,669	0	For
Dimensional	1,551,296	0	For
Woodline Partners LP	750,279	0	For
Polar Capital Holdings Plc	750,000	0	For
Wellington	632,081	0	For
Altium Capital Management LP	605,000	0	For
Soleus Capital Management, L.P.	598,000	0	For
BRAIDWELL LP	556,104	0	For
Candriam S.C.A.	0	353,000	Against
SILVERARC CAPITAL MANAGEMENT, LLC	343,358	0	For
Bridge Builder Trust	267,901	0	For
Columbia Threadneedle	254,901	0	For
HighVista Strategies LLC	247,880	0	For
Northern Trust	214,304	14	For
Direxion Shares ETF Trust	198,006	0	For

Showing the 25 largest of 143 asset managers. See all 143 in the interactive database.

2. Election of the three nominees for Class I director named in the accompanying proxy statement to hold office until the Company's 2027 Annual Meeting of Stockholders and until their successors have been duly elected and qualified: Gorjan Hrustanovic, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 44,334,757WITHHELD: 1,634,603

OLEMA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Gorjan Hrustanovic, Ph.D.”): 44,334,757 for, 1,634,603 withheld, per its Form 8-K filed 2024-06-14 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 55,867,863 outstanding shares: 79% for, 3% withheld (82% of the company cast a for/withheld vote).

The 49 asset managers below cast 100% of the shares they voted on this item FOR (7,853,325 for, 0 against).

FOR 85%ABSTAIN 15%

FOR: 7,853,325 (85.0%)ABSTAIN: 1,381,440 (15.0%)

Largest asset managers voting on “Election of the three nominees for Class I director named in the accompanying proxy statement to hold office u” at OLEMA PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	2,393,947	0	For
State Street	1,834,240	165	For
Dimensional	0	1,359,435	Abstain
BlackRock	768,979	0	For
Victory Capital	662,356	0	For
Altium Capital Management LP	605,000	0	For
Bridge Builder Trust	267,901	0	For
Columbia Threadneedle	254,901	0	For
Direxion Shares ETF Trust	198,006	0	For
Fidelity	153,133	0	For
TIAA	98,197	0	For
Charles Schwab	86,957	0	For
Goldman Sachs	72,861	0	For
Equitable	71,936	0	For
Jackson National	42,180	13,179	For
ProShares	51,591	0	For
Lincoln Financial	35,671	8,661	For
American Century	39,984	0	For
Prudential/PGIM	21,500	0	For
ALPS ETF Trust	21,074	0	For
T. Rowe Price	20,221	0	For
Global X	14,584	0	For
New York Life	13,321	0	For
AIG/SunAmerica	13,231	0	For
FORUM FUNDS II	10,868	0	For

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

3. Election of the three nominees for Class I director named in the accompanying proxy statement to hold office until the Company's 2027 Annual Meeting of Stockholders and until their successors have been duly elected and qualified: Ian Clark

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

74% Majority: yes · of votes cast

FOR 74%WITHHELD 26%

FOR: 33,874,399WITHHELD: 12,094,961

OLEMA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Ian Clark”): 33,874,399 for, 12,094,961 withheld, per its Form 8-K filed 2024-06-14 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 55,867,863 outstanding shares: 61% for, 22% withheld (82% of the company cast a for/withheld vote).

The 49 asset managers below cast 100% of the shares they voted on this item FOR (3,111,262 for, 0 against).

FOR 34%ABSTAIN 66%

FOR: 3,111,262 (33.7%)ABSTAIN: 6,123,503 (66.3%)

Largest asset managers voting on “Election of the three nominees for Class I director named in the accompanying proxy statement to hold office u” at OLEMA PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	2,393,947	0	For
State Street	1,942	1,832,463	Abstain
Dimensional	0	1,359,435	Abstain
BlackRock	0	768,979	Abstain
Victory Capital	0	662,356	Abstain
Altium Capital Management LP	605,000	0	For
Bridge Builder Trust	0	267,901	Abstain
Columbia Threadneedle	0	254,901	Abstain
Direxion Shares ETF Trust	0	198,006	Abstain
Fidelity	0	153,133	Abstain
TIAA	0	98,197	Abstain
Charles Schwab	86,957	0	For
Goldman Sachs	0	72,861	Abstain
Equitable	0	71,936	Abstain
Jackson National	0	55,359	Abstain
ProShares	0	51,591	Abstain
Lincoln Financial	0	44,332	Abstain
American Century	0	39,984	Abstain
Prudential/PGIM	0	21,500	Abstain
ALPS ETF Trust	0	21,074	Abstain
T. Rowe Price	0	20,221	Abstain
Global X	14,584	0	For
New York Life	0	13,321	Abstain
AIG/SunAmerica	0	13,231	Abstain
FORUM FUNDS II	0	10,868	Abstain

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

4. Election of the three nominees for Class I director named in the accompanying proxy statement to hold office until the Company's 2027 Annual Meeting of Stockholders and until their successors have been duly elected and qualified: Sandra Horning, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%13%

FOR: 40,102,098WITHHELD: 5,867,262

OLEMA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Sandra Horning, M.D.”): 40,102,098 for, 5,867,262 withheld, per its Form 8-K filed 2024-06-14 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 55,867,863 outstanding shares: 72% for, 11% withheld (82% of the company cast a for/withheld vote).

The 49 asset managers below cast 100% of the shares they voted on this item FOR (6,384,638 for, 0 against).

FOR 69%ABSTAIN 31%

FOR: 6,384,638 (69.1%)ABSTAIN: 2,850,127 (30.9%)

Largest asset managers voting on “Election of the three nominees for Class I director named in the accompanying proxy statement to hold office u” at OLEMA PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	2,393,947	0	For
State Street	1,831,895	2,510	For
Dimensional	0	1,359,435	Abstain
BlackRock	768,979	0	For
Victory Capital	0	662,356	Abstain
Altium Capital Management LP	605,000	0	For
Bridge Builder Trust	10,794	257,107	Abstain
Columbia Threadneedle	254,901	0	For
Direxion Shares ETF Trust	0	198,006	Abstain
Fidelity	153,133	0	For
TIAA	98,197	0	For
Charles Schwab	86,957	0	For
Goldman Sachs	0	72,861	Abstain
Equitable	71,936	0	For
Jackson National	0	55,359	Abstain
ProShares	0	51,591	Abstain
Lincoln Financial	22,900	21,432	For
American Century	0	39,984	Abstain
Prudential/PGIM	0	21,500	Abstain
ALPS ETF Trust	0	21,074	Abstain
T. Rowe Price	20,221	0	For
Global X	14,584	0	For
New York Life	13,321	0	For
AIG/SunAmerica	0	13,231	Abstain
FORUM FUNDS II	0	10,868	Abstain

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

5. Ratification of the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024.

AUDIT-RELATEDCompany result: Passed

Combines 2 wordings of this item as funds reported it.

99.9% Passed · of votes cast

FOR 99.9%

FOR: 48,366,695AGAINST: 19,160

OLEMA PHARMACEUTICALS INC.’s own tally for this item (“Proposal 3: Ratification of Selection of Independent Registered Public Accounting Firm Final Voting Results”): 48,366,695 for, 19,160 against — passed, per its Form 8-K filed 2024-06-14 (Item 5.07). Of all 55,867,863 outstanding shares: 87% for, 0.1% against (87% of the company cast a for/against vote).

The 49 asset managers below cast 100% of the shares they voted on this item FOR (9,234,765 for, 0 against).

FOR 100%

FOR: 9,234,765 (100.0%)

Largest asset managers voting on “Ratification of the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Com” at OLEMA PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Vote
Vanguard	2,393,947	For
State Street	1,834,405	For
Dimensional	1,359,435	For
BlackRock	768,979	For
Victory Capital	662,356	For
Altium Capital Management LP	605,000	For
Bridge Builder Trust	267,901	For
Columbia Threadneedle	254,901	For
Direxion Shares ETF Trust	198,006	For
Fidelity	153,133	For
TIAA	98,197	For
Charles Schwab	86,957	For
Goldman Sachs	72,861	For
Equitable	71,936	For
Jackson National	55,359	For
ProShares	51,591	For
Lincoln Financial	44,332	For
American Century	39,984	For
Prudential/PGIM	21,500	For
ALPS ETF Trust	21,074	For
T. Rowe Price	20,221	For
Global X	14,584	For
New York Life	13,321	For
AIG/SunAmerica	13,231	For
FORUM FUNDS II	10,868	For

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

6. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTESCompany result: Passed

98% Passed · of votes cast

FOR 98%

FOR: 45,174,223AGAINST: 787,068

The 2 asset managers below cast 100% of the shares they voted on this item FOR (250,394 for, 0 against).

FOR 100%

FOR: 250,394 (100.0%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at OLEMA PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Abstain	Withheld	Vote
ADAGE CAPITAL PARTNERS GP, L.L.C.	250,000	0	0	0	For
ALGERT GLOBAL LLC	394	0	0	0	For

Largest OLEMA PHARMACEUTICALS INC. shareholders voting in 2023-2024

Ranked by the number of OLEMA PHARMACEUTICALS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 55,867,863 shares outstanding at the time of that meeting.

Top OLEMA PHARMACEUTICALS INC. shareholders by shares voted, 2023-2024
#	Asset manager	% of shares outstanding
1	New York Life	32.24%
2	BVF INC/IL	16.35%
3	Paradigm Biocapital Advisors LP	7.75%
4	State Street	7.69%
5	Deep Track Capital, LP	4.92%
6	Vanguard	4.40%
7	MPM BioImpact LLC	3.51%
8	BlackRock	3.38%
9	Vivo Capital, LLC	3.35%
10	Logos Global Management LP	3.22%

Reported OLEMA PHARMACEUTICALS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

OLEMA PHARMACEUTICALS INC. beneficial owners on record for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
BlackRock	8.46%	13F
Vanguard Group	5.72%	13F
State Street	5.69%	13F
Morgan Stanley	2.78%	13F
Geode Capital	1.50%	13F
Wellington Management	1.50%	13F
Citadel Advisors	1.44%	13F
Goldman Sachs	1.44%	13F
Northern Trust	0.62%	13F

Percentages above are of 55,867,863 shares outstanding, as reported by OLEMA PHARMACEUTICALS INC. on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from OLEMA PHARMACEUTICALS INC.’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At OLEMA PHARMACEUTICALS INC.'s shareholder meeting held 2024-06-13, in the 2023-2024 proxy season, 147 asset managers reported how they voted in their SEC Form N-PX filings, covering 923 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Approval, on an advisory basis, of the compensation of the Company's named executive officers. — the proposal passed with 98% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: OLEMA PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-14.

OLEMA PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.